Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other 1Head & Neck 1

Conditions

Neoplasms 2Cancer Cachexia 2Pancreatic Neoplasms 1Mucositis 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × kang-lai-te × Clear all
NCT03101514 2021-06-23

Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study

First Affiliated Hospital of Harbin Medical University

Phase 2 Completed
53 enrolled 11 charts
Head & NeckOther

Head and Neck Neoplasms, Neoplasms, Mucositis

NCT00031031 2007-11-27

Kanglaite Injection Phase I Study

KangLaiTe USA

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡